With 150+ industry leaders attending the 2nd Gene Therapy for Ophthalmic Disorders’ don’t miss your chance to showcase your products and services, whilst establishing your company as a front runner in the field.
Meet industry scientists with the following expertize:
- CSO, CEO, CMO
From the likes of smaller biotechs such as Gensight Biologics, Adverum, REGENXBIO and SparingVision, as well as larger companies including Novartis and Biogen.
They're seeking preclinical models and services for:
- Inherited retinal disorders IRDs
- Wet age-related macular degeneration (AMD),
- Dry AMD
- Diabetic macular edema (DME),
- Leber hereditary optic neuropathy (LHON)
- And many more ophthalmic disorders
And other ocular diagnostic, endpoints and delivery technologies.
If you offer any services or products which could support this audience of ophthalmic experts, please get in touch here.